PMID- 26218262
OWN - NLM
STAT- MEDLINE
DCOM- 20160915
LR  - 20151105
IS  - 1557-7732 (Electronic)
IS  - 1080-7683 (Linking)
VI  - 31
IP  - 9
DP  - 2015 Nov
TI  - Safety and Efficacy of Intravitreal Preservative-Free Triamcinolone Acetonide 
      (Triesence) for Macular Edema.
PG  - 563-9
LID - 10.1089/jop.2015.0021 [doi]
AB  - PURPOSE: To evaluate the efficacy and safety of preservative-free triamcinolone 
      acetonide (Triesence) for the treatment of macular edema. METHODS: A 
      retrospective study was conducted on patients who attended a tertiary retinal 
      clinic from June 2009 to July 2012 with macular edema due to various causes. 
      Patients who received at least 1 intravitreal Triesence injection and completed 6 
      months of follow-up were recruited. Data, including best-corrected Snellen visual 
      acuity, central macular thickness (CMT), intraocular pressure (IOP), and adverse 
      events (AEs), were collected at baseline, week 1, month 1, month 3, and month 6 
      after initiation of treatment. Snellen visual acuity was converted to visual 
      acuity score (VAS) for statistical analysis using paired t-tests and linear 
      regression. RESULTS: One hundred two eyes from 102 patients were included in the 
      study. Mean VAS was significantly improved at all follow-up time points compared 
      to baseline (P</=0.002), with highest mean gain at month 1 (6.1+/-8.9 letters). Mean 
      CMT decreased significantly at all follow-up points compared to baseline 
      (P</=0.0005), with the greatest reduction at week 1 (146.6+/-109.4 mum). A total of 22 
      AEs were observed, and IOP elevation was the most common AE related to Triesence 
      treatment (17/22, 77.3%). No sterile or infectious endophthalmitis was observed. 
      CONCLUSION: Intravitreal Triesence improves visual acuity and reduces macular 
      thickness in eyes with macular edema from various causes. Treatment-associated 
      IOP elevation was manageable with antiglaucoma medications. There were no serious 
      vision-threatening complications associated with intravitreal Triesence therapy 
      during the study period.
FAU - Chang, Andrew A
AU  - Chang AA
AD  - 1 Sydney Retina Clinic and Day Surgery , Sydney, Australia .
AD  - 2 Save Sight Institute, Department of Clinical Ophthalmology and Eye Health, The 
      University of Sydney , Sydney, Australia .
FAU - Li, Haitao
AU  - Li H
AD  - 1 Sydney Retina Clinic and Day Surgery , Sydney, Australia .
FAU - Broadhead, Geoffrey K
AU  - Broadhead GK
AD  - 1 Sydney Retina Clinic and Day Surgery , Sydney, Australia .
AD  - 2 Save Sight Institute, Department of Clinical Ophthalmology and Eye Health, The 
      University of Sydney , Sydney, Australia .
FAU - Luo, Kehui
AU  - Luo K
AD  - 3 Department of Statistics, Faculty of Science and Engineering, Macquarie 
      University , Sydney, Australia .
FAU - Zhu, Meidong
AU  - Zhu M
AD  - 2 Save Sight Institute, Department of Clinical Ophthalmology and Eye Health, The 
      University of Sydney , Sydney, Australia .
LA  - eng
PT  - Journal Article
DEP - 20150728
PL  - United States
TA  - J Ocul Pharmacol Ther
JT  - Journal of ocular pharmacology and therapeutics : the official journal of the 
      Association for Ocular Pharmacology and Therapeutics
JID - 9511091
RN  - 0 (Glucocorticoids)
RN  - F446C597KA (Triamcinolone Acetonide)
SB  - IM
MH  - Aged
MH  - Female
MH  - Follow-Up Studies
MH  - Glucocorticoids/*administration & dosage/adverse effects
MH  - Humans
MH  - Intraocular Pressure/drug effects
MH  - Intravitreal Injections
MH  - Linear Models
MH  - Macular Edema/*drug therapy/etiology/pathology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
MH  - Triamcinolone Acetonide/*administration & dosage/adverse effects
MH  - Visual Acuity/*drug effects
EDAT- 2015/07/29 06:00
MHDA- 2016/09/16 06:00
CRDT- 2015/07/29 06:00
PHST- 2015/07/29 06:00 [entrez]
PHST- 2015/07/29 06:00 [pubmed]
PHST- 2016/09/16 06:00 [medline]
AID - 10.1089/jop.2015.0021 [doi]
PST - ppublish
SO  - J Ocul Pharmacol Ther. 2015 Nov;31(9):563-9. doi: 10.1089/jop.2015.0021. Epub 
      2015 Jul 28.